Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer

Area of Science:

• Oncology
• Cell Cycle Regulation
• Pharmacology

Background:

• The cyclin D-CDK4/6-Rb pathway is frequently altered in breast cancer, representing a key target for therapy.
• Palbociclib is a selective inhibitor of CDK4/6, demonstrating efficacy against Rb-positive cancer cell lines and xenografts.

Purpose of the Study:

• To review the cell cycle abnormalities in breast cancer and their link to estrogen signaling and endocrine resistance.
• To describe the pharmacological profile of palbociclib, its preclinical activity, and clinical development in breast cancer.
• To explore potential combination therapies and predictive factors for palbociclib treatment.

Main Methods:

• Literature search conducted via PubMed and major cancer congress proceedings.
• Review of preclinical data on palbociclib's activity and determinants of response.
• Analysis of clinical development and ongoing trials for palbociclib in breast cancer.

Main Results:

• Palbociclib inhibits proliferation in Rb-positive cancer models.
• Combination with endocrine agents shows significant promise.
• Combinations with HER2- and PI3K-inhibitors are potential avenues; chemotherapy combinations appear problematic.

Conclusions:

• Combination therapy with palbociclib and endocrine agents is a highly promising strategy for breast cancer.
• Further research is needed to validate predictive factors identified in preclinical studies for clinical application.
• Ongoing Phase III trials will confirm the efficacy of palbociclib-based combinations.